Status:
UNKNOWN
Risk Factors for Advanced Fibrosis Among FLD Patients
Lead Sponsor:
Helsinki University Central Hospital
Collaborating Sponsors:
Pfizer
Conditions:
NAFLD
Liver Cirrhosis
Eligibility:
All Genders
25-70 years
Brief Summary
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication. The o...
Detailed Description
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication. The o...
Eligibility Criteria
Inclusion
- Liver imaging results in the Helsinki University Hospital datalake 2010-2018 and a finding of fatty liver disease (without liver cirrhosis)
- Age 25-70 years(20-60 yrs at the time of the index imaging (2010-2018)
- Biobank consent with the Helsinki Biobank to be contacted for possible studies
Exclusion
- Liver cirrhosis at index imaging date; pregnancy; active treatment for cancer
Key Trial Info
Start Date :
August 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05971082
Start Date
August 24 2023
End Date
December 31 2025
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Hospital
Helsinki, Finland